IL6R and Autoimmunity: Satralizumab, a monoclonal antibody targeting IL-6R, is utilized in the treating of neuromyelitis optica spectrum disorder (NMOSD), a rare autoimmune disorder that primarily affecting the spinal cord and optic nerves.